Related Experiment Video

Updated: May 24, 2026

Pediatric Animal Model of Extracorporeal Cardiopulmonary Resuscitation After Prolonged Circulatory Arrest
04:55

Pediatric Animal Model of Extracorporeal Cardiopulmonary Resuscitation After Prolonged Circulatory Arrest

Published on: May 26, 2023

The use of anticoagulation in pediatric cardiac disease

J R Boris1, M A Harris

  • 1Division of Pediatric Cardiology, Keesler Medical Center, Keesler AFB, MS.

Images in Paediatric Cardiology
|February 28, 2012
PubMed

Insights

Pediatric anticoagulation for complex congenital heart defects is challenging due to limited research. This review defines current practices and highlights the need for more pediatric thromboembolism studies.

Area of Science:

  • Cardiology
  • Pediatric Medicine
  • Hematology

Background:

  • Complex congenital heart defects (CHDs) and new treatment contexts increase thromboembolism risk in children.
  • Established adult anticoagulation guidelines offer limited direct applicability to pediatric populations.

Purpose of the Study:

  • To review current anticoagulation strategies for pediatric patients with CHDs.
  • To synthesize existing pediatric and adult literature on cardiac anticoagulation.
  • To identify knowledge gaps and future research directions in pediatric anticoagulation.

Main Methods:

  • Literature review of pediatric disease states and anticoagulation.
  • Analysis of representative pediatric and adult scientific literature.
  • Synthesis of current practices in pediatric cardiac anticoagulation.

Main Results:

  • Limited specific studies exist for pediatric anticoagulation compared to adults.
  • Current pediatric anticoagulation relies on adapting adult protocols and expert consensus.
  • Several pediatric disease states present unique challenges for anticoagulation management.

Conclusions:

  • Pediatric cardiac anticoagulation is an evolving field requiring further research.
  • Standardization of anticoagulation protocols for pediatric CHDs is needed.
  • Future studies should focus on evidence-based guidelines for pediatric thromboembolism prevention and treatment.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Cardiac Catheterization I: Pre-Procedure Overview01:28

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...